Showing results (51-60 of 155) with videos related to

Sort By:
Pageof 16
Antimicrobial Agents and Chemotherapy|November 9, 2016
Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against ItselfPaul G Ambrose, Brian VanScoy, Haley Conde, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2006
Voriconazole therapeutic drug monitoringJ Smith, N Safdar, V Knasinski, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2025
Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infectionsScott A Van Wart, M Courtney Safir, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2019
Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection ModelOlanrewaju O Okusanya, Alan Forrest, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2018
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal ImpairmentChristopher M Rubino, Sujata M Bhavnani, Jeffery S Loutit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2024
Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility TestingThomas P Lodise, Sujata M Bhavnani, Paul G Ambrose, et al.
The Journal of Infectious Diseases|December 28, 2006
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growthTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
Diagnostic Microbiology and Infectious Disease|June 28, 2008
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumoniaSujata M Bhavnani, Alan Forrest, Jeffrey P Hammel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2007
Back to the future: using aminoglycosides again and how to dose them optimallyGeorge L Drusano, Paul G Ambrose, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2007
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populationsTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
Pageof 16